FREDERICK, MD. March 21, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices announced today that it has appointed Evomed (www.evomed.com.au) as the distributor for ActiPatch® Musculoskeletal Pain Relief Therapy, Allay® Menstrual Pain Relief Therapy and Smart Insole™ Heel Pain Relief Therapy in Australia and New Zealand.
Evomed specializes in the marketing and distribution of new and innovative healthcare products to both the hospital and retail pharmacy markets.
“We understand, specialize, and are committed to providing new and innovative medical solutions for pain relief.” said Rob Gourlay, Director of Sales and Marketing at Evomed. “ActiPatch is an award winning proven performer in overseas markets and we are excited to make it available to the Australian consumer.”
“Evomed will also be promoting the ActiPatch 7-Day Trial Device (RRP $9.95) to assist chronic pain sufferers with an affordable way to trial the device,” said Ben Fichter, Marketing Manager, BioElectronics Corporation. “Our United Kingdom 7-Day Trial program has seen over 100,000 patients use the device. A published registry of the results demonstrated over 65% of trial users obtain an average 57% reduction in their pain scores.”
The ActiPatch products launched this past weekend on the Gold Coast, Queensland at Australia’s premiere pharmacy trade show. The show attracts over 4,000 pharmacy professionals from across Australia and New Zealand.
About BioElectronics Corporation
BioElectronics Corporation (www.bielcorp.com) is a leader in non-invasive electroceutical and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses.
0 Comments Leave a comment